临床中的新型β-内酰胺酶抑制剂
New β-Lactamase Inhibitors in the Clinic.
作者信息
Papp-Wallace Krisztina M, Bonomo Robert A
机构信息
Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, 10701 East Boulevard, Cleveland, OH 44106, USA; Department of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, 10701 East Boulevard, Cleveland, OH 44106, USA; Department of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA; Department of Biochemistry, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA; Department of Pharmacology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA; Department of Molecular Biology and Microbiology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
出版信息
Infect Dis Clin North Am. 2016 Jun;30(2):441-464. doi: 10.1016/j.idc.2016.02.007.
Given the serious medical burden of β-lactamases, many approaches are being used identify candidate agents for β-lactamase inhibition. Here, we review two β-lactam-β-lactamase inhibitor (BL-BLI) combinations, ceftolozane-tazobactam and ceftazidime-avibactam that recently entered the clinic. In addition, we focus on BL-BLI combinations in preclinical development that have demonstrated activity in clinical isolates via susceptibility testing and/or in in vivo models of infection. We highlight only the BLIs that are able to reduce the Clinical Laboratory Standards Institute (CLSI) breakpoints for the BL partner into the susceptible range. Our analysis includes the primary literature, meeting abstracts, as well as the patent literature.
鉴于β-内酰胺酶带来的严重医疗负担，人们正在采用多种方法来鉴定β-内酰胺酶抑制的候选药物。在此，我们综述了两种β-内酰胺-β-内酰胺酶抑制剂（BL-BLI）组合，即最近进入临床的头孢洛扎/他唑巴坦和头孢他啶/阿维巴坦。此外，我们重点关注处于临床前开发阶段的BL-BLI组合，这些组合已通过药敏试验和/或感染的体内模型在临床分离株中显示出活性。我们仅强调那些能够将BL配对药物的临床实验室标准协会（CLSI）断点降低至敏感范围的β-内酰胺酶抑制剂。我们的分析包括原始文献、会议摘要以及专利文献。
Zotero 插件